Infliximab [infliximab biosimilar 3] (DrugBank: Infliximab)
25 diseasesID | Disease name (Link within this page) | Number of trials |
---|---|---|
35 | Pemphigus | 0 |
37 | Generalised pustular psoriasis | 1 |
38 | Stevens-Johnson syndrome | 0 |
39 | Toxic epidermal necrolysis | 0 |
40 | Takayasu arteritis | 0 |
41 | Giant cell arteritis | 0 |
42 | Polyarteritis nodosa | 0 |
43 | Microscopic polyangiitis | 0 |
45 | Eosinophilic granulomatosis with Polyangiitis | 0 |
46 | Malignant rheumatoid arthritis | 1 |
49 | Systemic lupus erythematosus | 0 |
50 | Dermatomyositis | 0 |
55 | Relapsing polychondritis | 0 |
56 | Behcet disease | 0 |
65 | Primary immunodeficiency | 0 |
84 | Sarcoidosis | 0 |
85 | Idiopathic interstitial pneumonia | 0 |
95 | Autoimmune hepatitis | 0 |
96 | Crohn disease | 1 |
97 | Ulcerative colitis | 1 |
98 | Eosinophilic gastrointestinal disease | 0 |
162 | Pemphigoid | 0 |
164 | Oculocutaneous albinism | 0 |
269 | Pyogenic arthritis | 0 |
271 | Ankylosing spondylitis | 0 |
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT03885089 (ClinicalTrials.gov) | October 21, 2019 | 4/3/2019 | Infliximab Biosimilar for Intravenous Drip Infusion 100 mg Pfizer Drug Use Investigation (Psoriasis) | Infliximab BS for Intravenous Drip Infusion 100 mg Pfizer General Investigation (Psoriasis Vulgaris, Psoriasis Arthropathica, Pustular Psoriasis, or Erythrodermic Psoriasis) | Psoriasis Vulgaris;Psoriasis Arthropathica;Pustular Psoriasis;Erythrodermic Psoriasis | Drug: Infliximab [infliximab biosimilar 3] | Pfizer | NULL | Recruiting | N/A | N/A | All | 100 | Japan |
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT03885037 (ClinicalTrials.gov) | March 20, 2019 | 4/3/2019 | Infliximab Biosimilar for Intravenous Drip Infusion 100 mg Pfizer Drug Use Investigation (Rheumatoid Arthritis) | Infliximab BS for Intravenous Drip Infusion 100 mg Pfizer General Investigation (Rheumatoid Arthritis) | Rheumatoid Arthritis | Drug: Infliximab [infliximab biosimilar 3] | Pfizer | NULL | Recruiting | N/A | N/A | All | 300 | Japan |
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT03884439 (ClinicalTrials.gov) | March 18, 2019 | 4/3/2019 | Infliximab Biosimilar Pfizer Drug Use Investigation (Crohn's Disease or Ulcerative Colitis) | Infliximab BS for Intravenous Drip Infusion 100 mg Pfizer General Investigation (Crohn's Disease or Ulcerative Colitis) | Crohn's Disease;Ulcerative Colitis | Drug: Infliximab [infliximab biosimilar 3] | Pfizer | NULL | Recruiting | N/A | N/A | All | 300 | Japan |
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT03884439 (ClinicalTrials.gov) | March 18, 2019 | 4/3/2019 | Infliximab Biosimilar Pfizer Drug Use Investigation (Crohn's Disease or Ulcerative Colitis) | Infliximab BS for Intravenous Drip Infusion 100 mg Pfizer General Investigation (Crohn's Disease or Ulcerative Colitis) | Crohn's Disease;Ulcerative Colitis | Drug: Infliximab [infliximab biosimilar 3] | Pfizer | NULL | Recruiting | N/A | N/A | All | 300 | Japan |